International journal of radiation oncology, biology, physics
-
Int. J. Radiat. Oncol. Biol. Phys. · Dec 2009
Multicenter StudyWhole pelvic radiotherapy versus prostate only radiotherapy in the management of locally advanced or aggressive prostate adenocarcinoma.
To determine whether whole pelvic radiotherapy (WPRT) or prostate-only radiotherapy (PORT) yields improved biochemical disease-free survival (BDFS) in patients with advanced or aggressive prostate adenocarcinoma. ⋯ WPRT may yield improved BDFS in patients with advanced or aggressive prostate adenocarcinoma, but results in a greater incidence of acute toxicity.
-
Int. J. Radiat. Oncol. Biol. Phys. · Dec 2009
Multicenter StudyRoles of radiation dose and chemotherapy in the etiology of stomach cancer as a second malignancy.
To evaluate the roles of radiation dose, chemotherapy, and other factors in the etiology of stomach cancer in long-term survivors of testicular cancer or Hodgkin lymphoma. ⋯ Stomach cancer risk is strongly radiation dose dependent. The role of chemotherapy, particularly of procarbazine and related agents, needs further study, because of the relatively small numbers of chemotherapy-treated subjects.
-
Int. J. Radiat. Oncol. Biol. Phys. · Oct 2009
Multicenter StudySurvey of stereotactic body radiation therapy in Japan by the Japan 3-D Conformal External Beam Radiotherapy Group.
To recognize the current status of stereotactic body radiotherapy (SBRT) in Japan, using a nationwide survey conducted by the Japan 3-D Conformal External Beam Radiotherapy Group. ⋯ The current status of SBRT in Japan was surveyed.
-
Int. J. Radiat. Oncol. Biol. Phys. · Sep 2009
Multicenter StudyDetermining the incidence of pain flare following palliative radiotherapy for symptomatic bone metastases: results from three canadian cancer centers.
To determine the incidence of pain flare following radiotherapy (RT) for painful bone metastases. ⋯ More than one third of the enrolled patients experienced a pain flare. Identifying at-risk individuals and managing potential pain flares is crucial to achieve an optimal level of care.
-
Int. J. Radiat. Oncol. Biol. Phys. · Sep 2009
Multicenter StudyMaximum vs. mono androgen blockade and the risk of recurrence in men with localized prostate cancer undergoing brachytherapy.
We examined whether maximum androgen blockade (MAB) is associated with a decreased recurrence risk vs. single-agent androgen suppression (monotherapy) for men undergoing brachytherapy (BT) for localized prostate cancer. ⋯ There are varied practice patterns in physicians' choice of the extent of concurrent ADT when used with brachytherapy for men with intermediate- or high-risk prostate cancer. Given a lack of demonstrated superiority from either ADT choice, both appear to be reasonable options.